1. The nascent field of AllergoOncology

   • Erika Jensen-Jarolim
   • Graham Pawelec

   Editorial 22 August 2012 Pages: 1355 - 1357

2. Implication of the β2-microglobulin gene in the generation of tumor escape phenotypes

   • Monica Bernal
   • Francisco Ruiz-Cabello
   • Federico Garrido

   Review 26 July 2012 Pages: 1359 - 1371

   

3. Pancreatic adenocarcinoma induces bone marrow mobilization of myeloid-derived suppressor cells which promote primary tumor growth

   • Matthew R. Porembka
   • Jonathan B. Mitchem
   • Peter Goedegebuure

   Original article 04 January 2012 Pages: 1373 - 1385

   

4. Photodynamic therapy–generated cancer vaccine elicits acute phase and hormonal response in treated mice

   • Mladen Korbelik
   • Soroush Merchant

   Original Article 24 January 2012 Pages: 1387 - 1394

   

5. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients

   • B. Schilling
   • E. S. Halstead
   • T. L. Whiteside

   Original Article 20 January 2012 Pages: 1395 - 1405

   

6. Quality of life during dendritic cell vaccination against metastatic renal cell carcinoma

   • Nicolai Leonhartsberger
   • Reinhold Ramoner
   • Martin Thurnher

   Original Article 26 January 2012 Pages: 1407 - 1413

   

7. Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer

   • Chun-Jian Qi
   • Yong-Ling Ning
   • Ke-Qing Qian

   Original article 31 January 2012 Pages: 1415 - 1424

   

8. Interleukin-1β enhances the production of soluble MICA in human hepatocellular carcinoma

   • Keisuke Kohga
   • Tomohide Tatsumi
   • Tetsuo Takehara

   Original Article 01 February 2012 Pages: 1425 - 1432

   

9. Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma

   • Shan Ren
   • Junfeng Lu
   • Lai Wei

   Original Article 04 February 2012 Pages: 1433 - 1439

   

10. Differential effects of low-dose decitabine on immune effector and suppressor responses in melanoma-bearing mice

    • Pierre L. Triozzi
    • Wayne Aldrich
    • Yogen Saunthararajah

    Original Article 05 February 2012 Pages: 1441 - 1450

    

11. Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

    • Christiane Sahm
    • Kurt Schönfeld
    • Winfried S. Wels

    Original article 05 February 2012 Pages: 1451 - 1461

    

12. Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer

    • Sandra Salvi
    • Vincenzo Fontana
    • Maria Pia Pistillo

    Original article 09 February 2012 Pages: 1463 - 1472

    

13. IL-15 augments antitumoral activity of an ErbB2/HER2 cancer vaccine targeted to professional antigen-presenting cells

    • Ute E. Burkhardt
    • Arjen Sloots
    • Winfried S. Wels

    Original article 14 February 2012 Pages: 1473 - 1484

    

14. A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions

    • Peggy J. de Vos van Steenwijk
    • Tamara H. Ramwadhdoebe
    • Sjoerd H. van der Burg

    Short communication Open access 09 June 2012 Pages: 1485 - 1492

    

15. Epidemiology: allergy history, IgE, and cancer

    • Michelle C. Turner

    Symposium-in-writing paper 20 December 2011 Pages: 1493 - 1510

16. The roles of mast cells in anticancer immunity

    • Dyana K. Dalton
    • Randolph J. Noelle

    Symposium-in-writing paper 18 April 2012 Pages: 1511 - 1520

    

17. How to connect an IgE-driven response with CTL activity?

    • Barbara Platzer
    • Eleonora Dehlink
    • Edda Fiebiger

    Symposium-in-writing paper 01 November 2011 Pages: 1521 - 1525

    

18. Involvement of eosinophils in the anti-tumor response

    • Solène Gatault
    • Fanny Legrand
    • Monique Capron

    Symposium-in-writing paper 17 June 2012 Pages: 1527 - 1534

    

19. Animal models for IgE-meditated cancer immunotherapy

    • Tracy R. Daniels
    • Otoniel Martínez-Maza
    • Manuel L. Penichet

    Symposium-in-writing paper 23 December 2011 Pages: 1535 - 1546

    

20. Recombinant IgE antibodies for passive immunotherapy of solid tumours: from concept towards clinical application

    • Sophia N. Karagiannis
    • Debra H. Josephs
    • Hannah J. Gould

    Symposium-in-writing paper 03 December 2011 Pages: 1547 - 1564

    

21. Recombinant IgE antibody engineering to target EGFR

    • Edzard Spillner
    • Melanie Plum
    • Ingke Braren

    Symposium-in-writing paper 07 June 2012 Pages: 1565 - 1573

    

22. Hypersensitivity to antineoplastic agents: mechanisms and treatment with rapid desensitization

    • Mariana Castells
    • Maria del Carmen Sancho-Serra
    • Maria Simarro

    Symposium-in-writing paper 11 May 2012 Pages: 1575 - 1584

    

23. IgE and chemotherapy

    • Martin H. Bluth

    Symposium-in-writing paper 03 December 2011 Pages: 1585 - 1590

24. Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer

    • Diana Mechtcheriakova
    • Martin Svoboda
    • Erika Jensen-Jarolim

    Symposium-in-writing paper Open access 19 April 2012 Pages: 1591 - 1598

    

25. Ninth annual meeting of the Italian Network for Tumor Biotherapy (NIBIT), Siena, Italy, October 19–22, 2011: New perspectives in the immunotherapy of cancer

    • Michele Maio
    • Hugues J. M. Nicolay
    • on behalf of NIBIT

    Meeting report 27 June 2012 Pages: 1599 - 1608